Drug Development
Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio
Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030
AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.
Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces
Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.
AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory
AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.
AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification
AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership
AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.
Lilly-backed Lycia Therapeutics Secures $106M for Clinical Trials on Lysosomal Protein Degraders
Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development